|Project Initiator: CEA Paris / François-Jacob Institute of Biology||Year(s) of Support: 2020-2021|
|Support Provided: Analyses, reagents||Amount Provided: 200,000 euros|
|Location: CEA, Fontenay-aux-Roses, France||
Air Liquide Monitor:
Géraldine Farjot, Air Liquide Santé International
The hypothesis of Paul-Henri Roméo's team and the partner teams is that the activation of the body’s protection mechanisms against oxidative stress can help the body fight the SARS-CoV-2 virus and limit viral replication. Indeed, the body develops defenses against inhaled oxidants to protect the lungs. The KEAP1/NRF2 antioxidant pathway, activated by these oxidants, makes a major contribution to this protection by enabling the expression of antioxidant proteins.
The goal of the research work is therefore to demonstrate the relevance of targeting the KEAP1/NRF2 antioxidant pathway for treating COVID-19.
The results of the work could have applications in combating SARS-CoV-2, but also other respiratory diseases involving a cytokine storm.
How It Works – The research program will take place in several phases:
The research project is conducted jointly by several research teams: